Trinity Biotech plc (TRIB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Trinity Biotech plc (TRIB) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-71.45K) by net assets ($-54.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Trinity Biotech plc - Cash Flow Conversion Efficiency Trend (1993–2024)
This chart illustrates how Trinity Biotech plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TRIB total liabilities for a breakdown of total debt and financial obligations.
Trinity Biotech plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trinity Biotech plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ECP Emerging Growth Ltd
AU:ECP
|
-0.023x |
|
Zacatecas Silver Corp
V:ZAC
|
-0.018x |
|
Barnwell Industries Inc
NYSE MKT:BRN
|
-0.216x |
|
Great Northern Minerals Ltd
AU:GNM
|
-0.073x |
|
Sinergi Inti Plastindo
JK:ESIP
|
0.003x |
|
City Steel Public Company Limited
BK:CITY
|
-0.003x |
|
Radius Gold Inc.
V:RDU
|
-0.098x |
|
ABM Fujiya Bhd
KLSE:5198
|
-0.091x |
Annual Cash Flow Conversion Efficiency for Trinity Biotech plc (1993–2024)
The table below shows the annual cash flow conversion efficiency of Trinity Biotech plc from 1993 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Trinity Biotech plc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-35.18 Million | $-4.19 Million | 0.119x | -75.31% |
| 2023-12-31 | $-23.95 Million | $-11.56 Million | 0.483x | +14.01% |
| 2022-12-31 | $-2.18 Million | $-921.00K | 0.423x | +101.02% |
| 2021-12-31 | $-319.00K | $13.24 Million | -41.498x | -287.64% |
| 2020-12-31 | $-2.22 Million | $23.75 Million | -10.705x | -1021.70% |
| 2019-12-31 | $4.71 Million | $5.47 Million | 1.161x | +637.81% |
| 2018-12-31 | $44.05 Million | $6.93 Million | 0.157x | -15.26% |
| 2017-12-31 | $65.20 Million | $12.11 Million | 0.186x | +46.68% |
| 2016-12-31 | $108.73 Million | $13.77 Million | 0.127x | +119.62% |
| 2015-12-31 | $213.89 Million | $12.34 Million | 0.058x | -27.88% |
| 2014-12-31 | $196.97 Million | $15.75 Million | 0.080x | +25.02% |
| 2013-12-31 | $183.01 Million | $11.71 Million | 0.064x | -45.98% |
| 2012-12-31 | $169.38 Million | $20.06 Million | 0.118x | -12.52% |
| 2011-12-31 | $151.33 Million | $20.48 Million | 0.135x | -17.11% |
| 2010-12-31 | $141.29 Million | $23.07 Million | 0.163x | -12.05% |
| 2009-12-31 | $79.34 Million | $14.73 Million | 0.186x | +14.05% |
| 2008-12-31 | $65.91 Million | $10.73 Million | 0.163x | +45.14% |
| 2007-12-31 | $136.84 Million | $15.35 Million | 0.112x | +154.62% |
| 2006-12-31 | $167.26 Million | $7.37 Million | 0.044x | -36.08% |
| 2005-12-31 | $133.62 Million | $9.21 Million | 0.069x | +18957.79% |
| 2004-12-31 | $116.14 Million | $42.00K | 0.000x | -99.19% |
| 2003-12-31 | $80.26 Million | $3.60 Million | 0.045x | -75.75% |
| 2002-12-31 | $62.91 Million | $11.65 Million | 0.185x | +106.90% |
| 2001-12-31 | $56.53 Million | $5.06 Million | 0.090x | +63.09% |
| 2000-12-31 | $55.04 Million | $3.02 Million | 0.055x | -67.36% |
| 1999-12-31 | $22.72 Million | $3.82 Million | 0.168x | +345.55% |
| 1998-12-31 | $14.60 Million | $-1.00 Million | -0.068x | +65.26% |
| 1997-12-31 | $7.10 Million | $-1.40 Million | -0.197x | +41.94% |
| 1996-12-31 | $10.60 Million | $-3.60 Million | -0.340x | -218.40% |
| 1995-12-31 | $7.50 Million | $-800.00K | -0.107x | +95.53% |
| 1994-12-31 | $1.30 Million | $-3.10 Million | -2.385x | -208.01% |
| 1993-12-31 | $3.10 Million | $-2.40 Million | -0.774x | -- |
About Trinity Biotech plc
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; se… Read more